PDF(1227 KB)
儿童成熟B细胞非霍奇金淋巴瘤临床特点及预后分析
陈再生, 郑湧智, 陈以乔, 高琴丽, 李健, 沈建箴
中国当代儿科杂志 ›› 2018, Vol. 20 ›› Issue (6) : 470-474.
PDF(1227 KB)
PDF(1227 KB)
儿童成熟B细胞非霍奇金淋巴瘤临床特点及预后分析
Clinical features and prognosis of children with mature B-cell non-Hodgkin's lymphoma: an analysis of 28 cases
目的 了解儿童成熟B细胞非霍奇金淋巴瘤（B-NHL）的临床特征和治疗结局。方法 28例患儿均以CCCG-B-NHL 2010方案化疗，其中20例联合美罗华治疗，随访31（4~70）个月。回顾性分析患儿的临床特征，以Kaplan-Meier法进行生存分析，并且进行预后因素的单因素分析。结果 28例患儿中伯基特淋巴瘤（BL）17例（61%），弥漫大B细胞型淋巴瘤（DLBCL）8例（29%），3 例（11%）未能进一步分类。首发表现为颈部肿物的13例（46%），颌面部肿物10例（36%），肝脾大9例（32%），腹部包块5例（18%），突眼5例（18%）。LDH<500 U/L者14例，500~1 000 IU/L者3例，≥1 000 IU/L者11例。化疗2疗程后，21例完全缓解、7例部分缓解，截至随访末期，24例持续完全缓解、4例复发。2年无事件生存率为85.7±6.6%。骨髓活检提示骨髓浸润、LDH≥500 IU/L、骨髓肿瘤细胞 > 25%的成熟B-NHL患儿2年累积生存率较低。结论 CCCG-B-NHL 2010方案联合美罗华治疗儿童B-NHL疗效满意，骨髓活检发现的骨髓浸润与不良预后相关。
Objective To study the clinical features and treatment outcome of children with mature B-cell non-Hodgkin's lymphoma (B-NHL). Methods A total of 28 previously untreated children with mature B-NHL were enrolled and given the chemotherapy regimen of CCCG-B-NHL-2010. Among them, 20 were given rituximab in addition to chemotherapy. The children were followed up for 31 months (ranged 4-70 months). A retrospective analysis was performed for the clinical features of these children. The Kaplan-Meier method was used for survival analysis. A univariate analysis was performed to investigate the prognostic factors. Results Among the 28 children, 17 (61%) had Burkitt lymphoma, 8 (29%) had diffuse large B-cell lymphoma (DLBCL), and 3 (11%) had unclassifiable B-cell lymphoma. As for the initial symptom, 13 (46%) had cervical mass, 10 (36%) had maxillofacial mass, 9 (32%) had hepatosplenomegaly, 5 (18%) had abdominal mass, and 5 (18%) had exophthalmos. Of all children, 14 had a lactate dehydrogenase (LDH) level of < 500 IU/L, 3 had a level of 500-1 000 IU/L, and 11 had a level of ≥ 1 000 IU/L. After two courses of chemotherapy, 21 children achieved complete remission and 7 achieved partial remission. At the end of follow-up, 24 achieved continuous complete remission and 4 experienced recurrence. The 2-year event-free survival rate was (85.7±6.6)%. The children with bone marrow infiltration suggested by bone marrow biopsy, serum LDH ≥500 IU/L, and bone marrow tumor cells > 25% had a low 2-year cumulative survival rate. Conclusions The CCCG-B-NHL 2010 chemotherapy regimen combined with rituximab has a satisfactory effect in the treatment of children with B-NHL. Bone marrow infiltration on bone marrow biopsy is associated with poor prognosis.
成熟B细胞非霍奇金淋巴瘤 / 美罗华 / 无事件生存率 / 预后 / 儿童
Mature B-cell non-Hodgkin's lymphoma / Rituximab / Event-free survival rate / Prognosis / Child
[1] El-Mallawany NK, Cairo MS. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma[J]. Clin Adv Hematol Oncol, 2015, 13(2):113-123.
[2] 中华医学会儿科学分会血液学组, 中国抗癌协会儿科专业委员会, 中华儿科杂志编辑委员会. 儿童非霍奇金淋巴瘤诊疗建议[J]. 中华儿科杂志, 2011, 49(3):186-192.
[3] Cerci JJ, Györke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma[J]. J Nucl Med, 2014, 55(10):1591-1597.
[4] Lee SH, Yoo KH, Sung KW, et al. Should children with non-Hodgkin lymphoma be treated with different protocols according to histopathologic subtype?[J]. Pediatr Blood Cancer, 2013, 60(11):1842-1847.
[5] Masahito T, Tetsuya M, Akira K, et al. Improved treatment results of children with B-Cell non-Hodgkin lymphoma:A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study[J]. Pediatr Blood Cancer, 2014, 61(11):1215-1221.
[6] Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence[J]. Br J Haematol, 2005, 131(1):39-49.
[7] Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives[J]. Pediatr Hematol Oncol, 2013, 30(6):465-483.
[8] 中华医学会儿科学分会血液学组,中国抗癌协会儿科专业委员会.中国儿童成熟B细胞非霍奇金淋巴瘤多中心诊治报告[J]. 中华儿科杂志, 2014, 52(9):649-654.
[9] 郭佳, 朱易萍, 高举, 等. 儿童成熟B细胞非霍奇金淋巴瘤急性淋巴细胞白血病43例临床及预后分析[J].中国实验血液学杂志, 2016, 24(1):72-79.
[10] 姜健,宋学文,徐慧娟,等.儿童非霍奇金淋巴瘤78例临床及预后分析[J].临床儿科杂志, 2015, 33(8):715-719.
[11] 孙晓非,甄子俊,夏奕,等. 改良NHL-BFM-90方案治疗儿童及青少年伯基特淋巴瘤和弥漫大B细胞淋巴瘤的远期疗效[J].中华血液学杂志, 2013, 34(12):1032-1037.
[12] 叶启东,潘慈,薛惠良,等. 104例B细胞非霍奇金淋巴瘤患儿疗效分析[J].中华血液学杂志, 2013, 34(5):399-403.
[13] Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children[J]. Br J Haematol, 2008, 142(3):329-347.
[14] Cheson BD. Role of functional imaging in the management of lymphoma[J]. J Clin Oncol, 2011, 29(14):1844-1854.
[15] Chen S,Wang S, He K, et al. PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients[J]. Eur Radiol, 2018 Jan 30. doi:10.1007/s00330-018-5306-5.[Epub ahead of print].
[16] Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement[J]. Blood, 2013, 122(1):61-67.
[17] Adams HJ, Kwee TC, Fijnheer R, et al. Bone marrow 18 F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma[J]. Am J Hematol, 2014, 89(7):726-731.
[18] Bhojwani D, McCarville MB, Choi JK, et al. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma[J]. Br J Haematol, 2015, 168(6):845-853.
[19] Sandlund JT. Non-Hodgkin Lymphoma in Children[J]. Curr Hematol Malig Rep, 2015, 10(3):237-243.
[20] Szczepanowski M, Lange J, Kohler CW, et al. Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents[J]. Br J Haematol, 2017, 179(1):116-119.
[21] Rohde M, Bonn BR, Zimmermann M, et al. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the NHL-BFM protocols[J]. Haematologica, 2017, 102(6):1091-1098.
福建省血液医学中心建设项目资助（闽政办（2017）4号）。国家和福建省临床重点专科建设项目资助。
